Search
Search Results
-
Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma
BackgroundThe purpose of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and...
-
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
PurposeThe presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication...
-
What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
To evaluate the effect of the 2018 ASCO/CAP guideline in the identification of HER2-positive breast carcinomas (BC) in reflex in situ hybridization...
-
Rare MDM2 amplification in a fat-predominant angiomyolipoma
Angiomyolipomas (AMLs) are triphasic tumors (smooth muscle, vascular and adipocytic components) with myomelanocytic differentiation, arising most...
-
The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society
PurposeThe effect of human epidermal growth factor receptor 2 (HER2) status on mucinous carcinoma (MC) of the breast is unknown due to the rarity of...
-
Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?
BackgroundHuman epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification are/is linked to a dismal outcome of...
-
Management of early breast cancer during the COVID-19 pandemic in Brazil
PurposeThe COVID-19 pandemic has impacted early breast cancer (EBC) treatment worldwide. This study analyzed how Brazilian breast specialists are...
-
Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
PurposeHuman epidermal growth factor-receptor-2 (HER2) is a membrane-tyrosine-kinase that is amplified/overexpressed up to 20% in breast cancer. HER2...
-
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
PurposeThe phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric...
-
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns
PurposeTo determine the biology, recurrence rate, metastatic patterns and survival times in primary triple-negative breast cancer (TNBC) with focus...
-
The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget’s disease
PurposeTo investigate the expression of biological markers in primary vulvar Paget’s disease (VPD).
MethodsForty-one patients referred to a single...
-
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
PurposeTo investigate the safety and efficacy of 30-min maintenance infusions of trastuzumab in advanced gastric cancer positive for human epidermal...
-
Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009
BackgroundTo describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these...
-
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor...
-
Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society
PurposeWe explored the association between parity and the risk of develo** a specific subtype of breast cancer. We also assessed the association...
-
Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization
The aims of this study were to evaluate and compare the HER2 gene amplification status in invasive and adjacent in situ breast carcinoma, using...
-
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient
Osimertinib is the best treatment choice for patients with epidermal growth factor receptor ( EGFR )-mutated advanced non-small-cell lung cancer...
-
A call to action: molecular pathology in Brazil
BackgroundAdoption of molecular pathology in Brazil is currently very limited. Of note, there are no programs for training new molecular pathologists...
